Drug Profile

BYN 002

Alternative Names: BYN-002; TL-001 - TrueLab Biopharmaceutical

Latest Information Update: 06 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator TrueLab Biopharmaceutical
Class Anti-inflammatories; Monoclonal antibodies
Mechanism of Action Tumour necrosis factor alpha modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Inflammatory bowel diseases

Most Recent Events

26 Jun 2026 TrueLab Biopharmaceutical completes enrolment in phase I trial for Inflammatory bowel diseases (In Volunteers) (IV) prior to Jun2 2026 (NCT06867796)
22 Jun 2026 BYN-002 licensed to Bionyra Pharma worldwide except Great China including China, Hong Kong, Macau, Taiwan
22 Jun 2026 Phase-I clinical trials in Inflammatory bowel diseases (In Volunteers) (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com